Liver fi brosis occurs during chronic injury and represents, in large part, an exaggerated matrigenic output by hepatic stellate cells (HSCs) which become activated as a result of injury-induced signaling pathways in parenchymal and infl ammatory cells (hepatocytes, macrophages, etc.). The molecular components in these pathways (e.g., CCN proteins) are modulated by transcription factors as well as by factors such as microRNAs (miRs) that act posttranscriptionally. MiRs are small (~23 nt) noncoding RNAs that regulate gene expression by specifi cally interacting with the 3′ untranslated region (UTR) of target gene mRNA to repress translation or enhance mRNA cleavage. As well as acting in their cells of production, miRs (and other cellular constituents such as mRNAs and proteins) can be liberated from their cells of origin in nanovesicular membrane exosomes, which traverse the intercellular spaces, and can be delivered to neighboring cells into which they release their molecular payload, causing alterations in gene expression in the target cells. Here we summarize some of the experimental approaches for studying miR action and exosomal traffi cking between hepatic cells. Insights into the mechanisms involved will yield new information about how hepatic fi brosis is regulated and, further, may identify new points of therapeutic intervention.
Introduction
Fibrosis arises due to the overt deposition of insoluble collagenous material during chronic organ injury. In the liver, fi brogenic cascades are triggered principally within hepatic stellate cells (HSCs) , which are ordinarily quiescent and store vitamin A in fat droplets but which undergo a process of activation during injury. HSC activation is characterized by a phenotypic transition of the cells into myofi broblasts which unrelentingly deposit collagen into the interstitial spaces during chronic injury [ 1 -3 ] . Pathways of fi brosis in the liver are initiated downstream of infl ammation and wound repair and are regulated by a broad variety of cytokines , growth factors , and matricellular proteins that include transforming growth factor-beta (TGF-β) as well as CCN1 and CCN2 [ 4 -8 ] . CCN2 is directly pro-fi brotic and often acts downstream of TGF-β to drive fi brosis. Whereas quiescent HSCs do not produce CCN2 or its receptors, CCN2 promoter activity is highly stimulated in HSC undergoing activation in vivo or in vitro, resulting in high levels of CCN2 mRNA expression and protein production [ 6 ] .
Recent evidence has shown that microRNAs ( miRs ) exert important regulatory actions in liver fi brosis . MiRs are small (~23 nt) noncoding RNA s that regulate gene expression by specifically interacting with the 3′ untranslated region (UTR) of target gene mRNA to repress translation or enhance mRNA cleavage [ 9 ] . We have recently identifi ed a binding site for miR-214 in the CCN2 3′-UTR [ 10 ] . High levels of miR-214 in non-injured liver or quiescent HSC engage the CCN2 3′-UTR and inhibit CCN2, thus contributing to suppressed expression of CCN2 under resting (non-pathological) conditions. In contrast the levels of miR-214 are highly diminished in fi brotic liver or activated HSC , allowing CCN2 expression to be manifested [ 11 ] .
A very new area of research relates to the manner in which fi brosis is regulated by exosomes. Exosomes are 50-150 nm membranous vesicles that arise by inward budding from the limiting membranes of multivesicular bodies (MBV). Upon fusion of MVBs with the plasma membrane, exosomes are liberated from the cells, and traverse intercellular spaces , and may be taken up by neighboring cells [ 12 -14 ] . Exosomes contain a complex mixture of miRs , mRNAs, and proteins and therefore their uptake by target cells represents a novel communication pathway through which molecular information is exchanged between donor and recipient cells. MiR-214 is exosomally shuttled between neighboring HSCs and can exert epigenetic effects on the CCN2-UTR in recipient cells [ 11 , 15 ] .
Materials
Whenever possible, reagents and drugs administered to animals are to be of pharmaceutical grade . Controlled substances should be locked securely with access restricted only to authorized individuals. Meticulous record-keeping for all drugs is essential. Animal protocols require institutional approval.
1. Perfusion solution: 1× PBS , pronase, collagenase IV. Add pronase (1.33 mg/ml) and collagenase IV (0.5 mg/ml) into PBS (1×) before use.
2. Digest solution: Dulbecco's modifi ed Eagle medium / nutrient mixture F-12 ( DMEM /F-12 ), pronase, DNase I . Dissolve pronase (1 mg/ml) and DNase I (1 mg/ml) into DMEM /F-12 medium before use. 2. Anesthetize mice with ketamine (66 mg/kg) and xylazine (14 mg/kg) and ensure a very deep plane of anesthesia by strong toe pinch . Optionally, blood (0.5-0.7 ml) is collected by cardiac puncture using a 25-gauge needle. Cardiac function will be compromised but the heart will still beat slowly. Place animal on its back and spray the abdomen with 70 % alcohol . Access the liver through an abdominal incision . Introduce a 22GA needle (1.00IN, 0.9 × 25 mm) into the infra-hepatic vena cav a and snip the portal vein with scissors. Initiate systemic perfusion of 20-30 ml PBS (results in immediate death) followed by the perfusion solution.
HSC Isolation Components
3. Remove perfused livers from fi ve mice, mince with scissors, and digest in the digest solution.
4. Stop the digestion with 3 ml serum and centrifuge at 300 × g for 10 min (4 °C). Rinse the pellets and centrifuge them again under the same conditions.
5. Filter the resulting cell suspension through a metal sieve (120 μm) and centrifuge at 300 × g for 10 min (4 °C) and then remove the supernatant .
6. Prepare the gradient solutions .
7. Resuspend the cell pellet in 15 % OptiPrep gradient solution and place in a centrifuge tube. Over the top of this solution, layer the 11 % OptiPrep gradient solution , followed by HBSS on top of that. Centrifuge the resulting cell suspension at 1400 × g for 30 min without braking. HSCs separate into a hazy band just above the interface of the gradient in the aqueous buffer. Harvest the band.
8. Wash the band of cells and resuspend them at 10 5 cells/ml in the culture medium .
9. Plate the cells into fl asks or multi-well plates as needed.
10. Verify HSC identity and purity by buoyant density , phasecontrast microscop y, oil red staining , and immunostaining for glial fi brillary acidic protein (GFAP) or desmin ( see Note 1 ). Immunostaining can also be performed for additional markers such as alpha smooth muscle actin (αSMA) , connective tissue growth factor (CCN2), or collagen 1(α1) which are induced in the cells as they become autonomously activated in culture.
Isolation of Mouse HSC
1. Tissue preparation : Superior results are obtained by perfusion of the liver to remove blood components. Follow the procedure in Subheading 3.1 , step 2 , except that the surgical approach is to make a V-cut through the skin and abdominal wall about 1 cm caudal to the last rib. Make a small incision in the diaphragm to equalize the heart chamber and external pressures , lift the sternum upwards, cut the rib cage laterally about 1 cm in each direction to access the heart chamber , insert a 23-25-gauge butterfl y needle into the left ventricle , and clip the aorta with scissors.
2. Perfuse animals with 20-30 ml 4 % paraformaldehyde for fi xation. Resect the liver and place in 4 % paraformaldehyde overnight at 4 °C. Wash fi xed livers three times with 70 % ethanol before embedding in paraffi n blocks. Cut sections of 6 μm and mount on slides ( see Note 2 ). As an alternative approach, one lobe of the livers is tied off with suture material after PBS perfusion (for later RNA extraction ) prior to perfusion of the remainder of the liver with 4 % paraformaldehyde . The various lobes are then processed for histology as above or frozen for RNA extraction ( see Subheading 3.5 ).
3. Hybridization is performed as described in the instructions for the miRCURY LNA™ microRNA ISH optimization kit.
4. De-paraffi nize the liver sections with xylene and ethanol solutions at room temperature by placing with sections in a slide rack, and then move among jars according to Table 2 , ending up in PBS .
5. Incubate with proteinase-K for 10 min at 37 °C ( see Note 3 ) and wash twice with PBS . Dehydrate the sections in graded alcohol (Table 3 ) and air-dry the slides on clean paper towels for 15 min.
6. Place the slides on a fl at surface and hybridize the sections with a probe in microRNA ISH buffer for the microRNA of interest (e.g., miR-214 for CCN2) or scramble sequence probes ( see Note 4 ).
7. Apply sterile and RNase-free glass cover slips onto the sections and seal along all four edges with Fixogum for 60 min at 55 °C ( see Note 5 ).
8. Remove Fixogum using tweezers and carefully detach cover slips. Place the slides in 5× SSC solution. Wash the slides with varying concentrations of SSC buffer at 55 °C as shown in Table 4 ( see Note 5 ).
9. Incubate the slides with anti-digoxigenin-alkaline phosphatase antibody (1:800) for 60 min after blocking the sections with block solution. 11. Counterstain the slides with Nuclear Fast Red™, dehydrate the slides in graded ethanol solutions according to Table 3 , mount with Eukitt ® Medium, and examine by confocal microscopy .
1. Fix HSC with 2.5 % glutaraldehyde for 30 min, wash with 4.5 % sucrose in PBS , and then permeabilize the cells with 0.3 % Triton X-100 in PBS for 15 min, followed by PBS-T for 5 min.
All steps are at room temperature .
2. Incubate HSC with proteinase-K for 10 min at 37 °C ( see Note 6 ) and fi x the cells with 4 % paraformaldehyde for 5 min at room temperature . Wash HSC with PBS -T and treat the cells with 50 % formamide/2× SSC before hybridization .
3. Hybridize HSCs with probe (s) to the microRNA of interest (e.g., miR-214 for CCN2) or with a scrambled sequence ( see Note 7 ) for 30 min at 58 °C in microRNA ISH buffer followed by washes with graded concentrations of SSC buffer (Table 4 ) at 58 °C. Mount cells in Prolong Gold Mounting Medium with DAPI and examine by confocal microscopy .
1. De-paraffi nize liver sections with xylene and ethanol as described above (Table 2 ) . Fix cultured HSC with 4 % paraformaldehyde for 1 h at room temperature and then rinse the cells three times with PBS .
2. Incubate liver sections or mouse HSC with blocking reagent for 1 h at room temperature .
3. Rinse and apply primary antibodies against CCN2 (5 μg/ml), αSMA (1:100), or collagen 1(α1) (1:250) overnight at 4 °C with mixing.
4. Rinse the sections four times with PBS -T, 15 min each time.
5. Add, respectively, Alexa Fluor ® 488 goat-anti-chicken IgY, Alexa Fluor ® 568 goat-anti-rabbit IgG, or Alexa Fluor ® 647 goat anti-mouse IgG (all at 1:1000) for 1 h at room temperature .
6. Rinse the sections three times in PBS -T for 15 min and one time in PBS for 15 min at room temperature with agitation .
7. Mount the slides with Vectashield Mounting Medium and examine by fl uorescence or confocal microscopy .
1. Extract total RNA (including microRNAs) from frozen tissues or cultured HSC using a microRNeasy mini kit according to the manufacturers' protocols.
2. Reverse transcribe RNAs into cDNAs using a miScript II RT kit according to the manufacturers' protocols. 2. For mouse, amplify the full-length 997 bp 3′-UTR of CCN2 (Genbank SEQ ID: BC006783.1) by PCR from primary mouse HSC genomic DNA using forward primer 5′-GAGGGATCCGTCACACTCTCAACAAATAAAC TGCCC-3′ and reverse primer 5′-GAGGAATTCAGCC AGGAAGTAAGGGAACCGAACTCA-3′ (Fig. 1a ) .
3. Digest the PCR fragment with BamH I and EcoR I and then subclone CCN2 3′-UTR into Fire-Ctx sensor lentivector, downstream of the Firefl y luciferase reporter and cytotoxin ( CTX ) drug sensor genes. Verify the construction by DNA sequencing (Fig. 1b ) .
4. Incorporate a 5-base mutation into the CCN2 3′-UTR at the predicted binding site for the miR of interest (e.g., GTCCG → ACAAT for miR-214 ; Fig. 1a ). Amplify the mutated form of CCN2 3′-UTR from the wild-type UTR using relevant primers (e.g., forward primer 2. Measure luciferase activity in triplicate using an E1910 Dual Luciferase Reporter Assay System after 24 h. Use Renilla luciferase activity for normalization, and compare fi refl y luciferase activity in pre-mir-214 transfected cells to that in mocktransfected cells.
miR-Selection
3. Alternatively, 24 h after transfection, treat the cells with CTX reagent (1:1000) for 3-4 days. Assess the cell viability using a CytoSelect™ assay.
1. Harvest exosomes from HSC cultures by subjecting HSCconditioned medium to a low-speed centrifugation step (e.g., 10,000 × g for 20 min at 4 °C) from which the supernatant is then subjected to ultracentrifugation at 100,000 × g for 90 min at 4 °C. The supernatant is removed and pellet is resuspended in 1 ml of cold (4 °C) PBS and then subsequently ultracentrifuged at 100,000 × g for 90 min at 4 °C. Resuspend the pellet in 250-500 μl PBS.
2. Harvest circulating exosomes from serum using PureExo Exosome Isolation Kit.
3. Perform dynamic light scattering (632.8 nm laser, 90 o detection angle) using a BI 200SM Research Goniometer System to establish the size range of the exosomes. 4 . Use a ZetaPALS analyzer to establish zeta potential (net charge) of the exosomes.
5. Perform transmission electron microscopy (TEM) to establish exosome size and morphological characteristics. Coat exosomes on to carbon-coated 400 mesh copper grids, stain with 2 % uranyl acetate, air-dry , and image by TEM with an H-7650 microscope. Alternatively, to preserve membrane integrity and morphology , coat exosomes on to carbon-coated grids, blot the surface to dry it, and then plunge-freeze in liquid nitrogencooled ethane slush. Cryogenic TEM is performed using a Tecnai G2 F20 microscope (Fig. 2 ) ( see Note 9 ).
6. Perform SDS-PAGE and Western blot analysis to verify the presence of well-characterized exosome markers (e.g., CD9,
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CD81). Resuspend the exosome-rich pellet in loading buffer, separate on a polyacrylamide gel , and transfer to a nitrocellulose membrane using transfer buffer. Block the membrane with blocking reagent and incubate fi rst with a CD9 antibody overnight at 4 °C, followed by goat anti-rabbit HRP secondary antibody (1:2000) for 1 h at room temperature . Detect the immunoreactive CD9 protein band by enhanced chemiluminescence .
1. Transfect P6 primary mouse HSC with pre-mir-214 (100 nM) by electroporation , and incubate the cells in fresh serum-free DMEM /F12 medium in T-75 culture fl asks for 36 h. Controls include non-treated or mock-transfected cells.
2. Harvest and purify exosomes released into the conditioned medium . Isolate total RNA from 200 μg exosomes using miRNeasy mini kits as described above. Run triplicate RT-PCR reactions for the miRs of interest. Normalize the data to an unchanged constituent, e.g., let-7a ( see Note 10 ).
3. Evaluate exosomal proteins by Western blot as described in Subheading 3.8 , step 6 .
Exosome components can be fl uorescently tagged to allow visualization after addition to target cells ( see Note 11
). Either (a) mix exosome-enriched cell medium with fl uorescent dye PKH26 (4 mM) for 1 h and then purify the stained exosomes as in Subheading 3.8 , step 1 , or (b) transfect mouse HSC with 4 μg CD9-GFP or miR-214 RFP plasmids by electroporation , incubate the transfected cells in fresh serum-free DMEM /F-12 medium in T-75 culture fl asks for 48 h, and then collect exosomes from the medium as in Subheading 3.8 , step 1 .
2. Add aliquots of exosomes to mouse HSC cultures for 2-48 h and examine for PKH26, GFP , or RFP fl uorescence using con- Fig. 2 Transmission electron microscopy of HSC-derived exosomes. Exosomes were isolated by sequential centrifugation of conditioned medium from P6 mouse HSC. TEM ( left ) and cryogenic TEM ( right )
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Assessment of Exosomal Uptake and Action in Target Cells
focal microscopy ( Fig. 3 ) . Alternatively, wash the recipient cells with PBS , lyse the cells in RIPA buffer, and measure fl uorescent intensity of cell lysates .
3. Exosome effects in recipient cells are assessed by determining changes in levels of key target molecules (e.g., CCN2, αSMA, collagen 1(α1) at the RNA or protein level). Alternatively, the effects can be measured in terms of altered activity of relevant gene reporters that were transfected into the recipient prior to exosome treatment.
The Culture-Insert is made from biocompatible silicone material and is divided into two wells by a central silicone wall that can be cut away and removed from the system (Fig. 4 ) ( see Note 12 ). 3. If donor cells were stained (e.g., using PKH26, GFP , RFP , SYTO RNA Select Green), assess transfer of the stain to recipient cells by direct fl uorescence microscopy ( see Note 16 ).
4. Measure the luciferase activity in triplicate in recipient cells using the dual luciferase reporter assay system. Firefl y luciferase activity in miR-214 -transfected cells is compared to that in nontransfected cells, with Renilla luciferase activity used for normalization. Luciferase activity is decreased upon exposure of the recipient cells to the donor cells. Proof that donor exosomes are mediating this effect will be seen by failure of CCN2-UTR activity to be regulated in the presence of GW4869-treated donor cells. Proof that exosomally delivered miR-214 directly targets CCN2-UTR is shown by failure of luciferase activity to be regulated in recipient cells transfected with the mutant CCN2-UTR.
Notes
1. Freshly isolated HSCs contain cytoplasmic lipid droplets which are visualized by uptake of oil red O stain. Fix the cells in icecold 4 % paraformaldehyde in PBS for 20 min at room temperature prior to incubation for 10 min in a saturated solution of oil red O (Polysciences, Warrington, PA) in isopropanol (Sigma-Aldrich).
2. Prepare all solutions using RNase-free water. 4. For identifying the optimal probe concentration, it is recommended to test the double-DIG-labeled LNA ™ microRNA probe and the LNA™ scrambled microRNA probe at 1-200 nM. Denature the LNA™ probes at 90 °C for 4 min before using.
5. For identifying the optimal hybridization temperature , it is recommended to test at 55 °C. At low temperature the LNA™ probes give higher signal , but the risk of cross-hybridization to highly similar sequences is increased. However, the LNA™ probes give weaker signal at high temperature .
6. The Proteinase-K concentration range must be optimized for individual cells. It is recommended to test with 1 μg/ml.
7.
For identifying the optimal probe concentration, it is recommended to test the double-DIG-labeled LNA™ microRNA probe and the LNA™ scrambled microRNA probe at 1-200 nM. Denature the LNA™ probes at 90 °C for 4 min before using.
8. To gain the highest transfection effi ciency or gene expression activity, it is recommended to use electroporation system for transfection.
9. Cryogenic TEM preserves the structure of exosomes and allows visualization of exosomes as translucent particles with an outer bilayer membrane [ 16 ] .
10. To identify optimal reference gene(s), it is recommended to test stable microRNAs or small RNAs (e.g., 5S rRNA , U6 snRNA) as controls [ 17 -19 ] .
11. Alternatively, stain the cells with SYTO RNASelect green (Thermofi sher). This selectively stains RNA, resulting in a fl uorescent signal in exosomes that can be subsequently detected in the target cells, indicative of exosomally delivered RNA.
12. Use specifi ed immersion oils (Immersol 518F and Immersol W2010 from Zeiss, or Immersion liquid from Leica) when applying to oil immersion objectives. The use of a nonrecommended oil could lead to the damage of the plastic material and the objective.
13. If endogenous levels of the miR of interest are low in the donor cells, then they can be transfected with the appropriate miR mimic , with or without a fl uorescent tag.
14. GW4869 blocks neutral sphingomyelinase2 (nSMase2) which is required for the biosynthesis of ceramide on which exosome production is dependent. Alternatively, use siRNA to block nSMase 2 or components of exosome biogenic pathways (e.g., Rab proteins).
15. Control experiments include exposure of recipient HSC to cellfree donor micro-wells containing pre-mir-214 in the medium at the same concentration as used for donor HSC transfection.
16. For ease of identifi cation, the recipient cells can be pre-stained with a differently fl uorescing vital dye such as PKH67.
